| Autor: |
Inzaule, Seth C, Hamers, Raph L, Noguera-Julian, Marc, Casadellà, Maria, Parera, Mariona, Kityo, Cissy, Steegen, Kim, Naniche, Denise, Clotet, Bonaventura, Rinke de Wit, Tobias F, Paredes, Roger, Osibogun, Akin, Wallis, Carole L., Nalubwama, Cathy, Letsoalo, Esrom, Senono, Fred, Adelabu, Hameed, Kakooza, Hanipha, Namata, Harriet, Sanne, Ian, Nankya, Immaculate, Menke, Jack, Lange, Joep M.A., Sigaloff, Kim C.E., Mandaliya, Kishor, Hardman, Margaret, Siwale, Margaret, de Jager, Marleen, Dolan, Marian, Botes, Mariette E., O'Mello, Martin, Wellington, Maureen, Mutebi, Miiro, Nakitto, Miriam, Labib, Moheb, Pakker, Nadine, Ondoa, Pascale, Mugyenyi, Peter, Ive, Prudence, Nakanjako, Ritah, Schuurman, Rob, Lüthy, Ruedi, Balinda, Sheila N., Akanmu, Sulaimon, Boender, T. Sonia, Adeyemo, Titilope A., Rodoye, Tope, Stevens, Wendy S., Namala, Winnie |
| Zdroj: |
The Lancet HIV; November 2018, Vol. 5 Issue: 11 pe638-e646, 9p |
| Abstrakt: |
Implementation of ultrasensitive HIV drug resistance tests for routine clinical use is hampered by uncertainty about the clinical relevance of drug-resistant minority variants. We assessed different detection thresholds for pretreatment drug resistance to predict an increased risk of virological failure. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
